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Abstract
Background The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed
to account for cultural and healthcare system differences across European countries (EC).
Objective To utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Der-
matology Life Quality Index (DLQI).
Methods The MAPP survey was conducted between June and August 2012. This analysis included 1700 patients with
self-reported psoriasis (without psoriatic arthritis) from France (n = 349), Germany (n = 311), Italy (n = 359), Spain
(n = 354) and the United Kingdom (n = 327).
Results Patients from Spain vs. other EC self-reported higher mean body mass index (26.9 vs. 25.6, P ≤ 0.001), lower
prevalence of depression (6% vs. 12%, P = 0.002) and higher mean self-perceived psoriasis severity at its worst (5.92
vs. 5.33, P < 0.001) despite lower estimated body-surface-area involvement. Overall, patients from Spain vs. other EC
had lower mean global DLQI scores (4.70 vs. 6.06, P = 0.001) and lower mean scores for each DLQI dimension [all
P < 0.001, except leisure (P = 0.002), treatment (P = 0.002), and work and school (P = 0.005)]. Higher DLQI values were
inversely associated with age and directly correlated with perceived severity. Palmoplantar, nail and scalp psoriasis were
reported less frequently in Spanish patients (P = 0.026) and were associated with higher DLQI values (P < 0.01). Spanish
patients were more likely to have seen multiple healthcare providers (HCPs; P < 0.001) and achieve therapeutic goals
(P < 0.001), but current treatments were similar to patients in other EC.
Conclusions In the MAPP survey, Spanish patients differed from other EC in several characteristics, including comor-
bidities, extent and distribution of psoriasis lesions, perception of severity and impact on quality of life. Their perception
of psoriasis severity was higher despite a lower estimated extent, and DLQI scores were signiﬁcantly lower. Spanish
patients had more HCP visits and a higher rate of therapeutic goal achievement. These differences might be attributed to
cultural factors, phenotypical variation and differences in HCP access.
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Introduction
The Multinational Assessment of Psoriasis and Psoriatic Arthri-
tis (MAPP) was a systematic household telephone survey (using
random digit dialling to provide a probability sample) of
139 948 households in the United States, Canada, France, Ger-
many, Italy, Spain and the United Kingdom (UK) designed to
identify adults with a previous diagnosis of psoriasis and/or pso-
riatic arthritis.1 Interviews were conducted with 3426 patients,
corresponding to approximately 1000 adults in the United States
and 400 in each of the other countries. The MAPP survey lacked
bias because participants were not limited to a specific clinic or
geographic region and did not have to be under the medical care
of a healthcare provider (HCP) or enrolled in a patient associa-
tion at the time of the survey; in addition, validated quality-of-
life assessments were used for the survey, such as the Dermatol-
ogy Life Quality Index (DLQI).1 The DLQI is easy to use in clini-
cal practice and has been employed in clinical trials of psoriasis2
and for reimbursement purposes in some health systems; how-
ever, patients with psoriasis from different countries respond
differently to a substantial proportion of DLQI items despite
having the same level of underlying health-related quality-of-life
(HRQoL) impairment.3
Differences in responses between patients in North America
and Europe were primarily related to joint disease and symp-
toms. Almost twice as many North Americans experienced joint
symptoms first vs. Europeans (24% vs. 13%).1 In addition,
greater proportions of North Americans vs. Europeans with
psoriasis who did not have a diagnosis of psoriatic arthritis
reported joint pain (51% vs. 36%) and had more than four
joints affected (49% vs. 30%).1 Thus, for the sake of homogene-
ity, in this subanalysis, we included only patients with psoriasis
without a diagnosis of psoriatic arthritis from European coun-
tries (EC).
The aims of this exploratory, descriptive, observational and
cross-sectional study were to analyse and compare the DLQI
results and assess other response variables in patients who had a
diagnosis of psoriasis without psoriatic arthritis in Spain vs.
other EC included in the MAPP study.
Materials and methods
The MAPP patient survey has been published previously.1 The
European subset analysed in this study included 1700 patients
with psoriasis (without psoriatic arthritis) from France
(n = 349), Germany (n = 311), Italy (n = 359), Spain (n = 354)
and UK (n = 327). The primary response variable was the DLQI
score, which is calculated by summing the score of questions
designed for use in adults, resulting in a maximum score of 30
and a minimum score of 0. The questions are grouped into six
subscales as follows: symptoms and feelings (questions 1 and 2),
daily activities (questions 3 and 4), leisure (questions 5 and 6),
work and school (question 7), personal relationships (questions
8 and 9) and treatment (question 10). To help the clinical inter-
pretation of the DLQI scores, a banding system (consisting of
five bands) has been validated.4 According to this system, a
DLQI score of 0–1 indicates no effect at all on a patient’s life, 2–
5 indicates a small effect, 6–10 indicates a moderate effect, 11–20
indicates a very large effect and 21–30 indicates an extremely
large effect. Secondary response variables were the DLQI sub-
scales and bands. Explanatory variables included country (pri-
mary variable), gender, age, palmar and/or plantar involvement,
nail involvement, scalp involvement and self-perceived severity,
which were rated on a scale from 1 to 10, with scores categorized
as mild (1–3), moderate (4–7) and severe (8–10), and extent of
the involved area at the time of the survey self-assessed in palms
roughly equivalent to 1% of body-surface-area (BSA) involve-
ment.5
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Data management and statistical analyses were performed
using R version 3.1 (The R Project for Statistical Computing,
The R Foundation, Vienna, Austria; http://www.r-project.org).
Bivariate analyses have been performed using the chi-square test,
Fisher’s exact test or likelihood ratio chi-square test for qualita-
tive variables, and the analysis of variance, Mann–Whitney–Wil-
coxon test or Kruskal–Wallis test for quantitative variables. The
compliance of application conditions was determined using the
Shapiro–Wilk and Kolmogorov–Smirnov normality tests and
the Levene’s test for homogeneity of variances. Multivariate gen-
eralized linear models have been used, taking into account the
nature of the distribution of each response variable. For all sta-
tistical tests, a nominal significance level of 5% (P < 0.05) has
been applied.
Results
In the global MAPP patient survey, the self-reported prevalence
of psoriasis and/or psoriatic arthritis ranged from 1.4% in Spain
to 3.3% in Canada.1 The mean age of the total study population
(N = 3426) was 54.8 years, and 21% were also diagnosed with
psoriatic arthritis. Among patients with psoriasis only, 27%
rated their disease as severe. Self-perceived severity correlated
with BSA involvement overall; however, 22% of patients with
psoriasis and BSA involvement of three or fewer palms reported
a substantial disease-related impact on daily life. The most both-
ersome symptoms were itching (43%), scaling (23%) and flaking
(20%). Of the patients with psoriasis, nearly half (47%) had not
seen an HCP in a year, and more than 80% with BSA involve-
ment of four or more palms were not receiving systemic treat-
ment.1
For the current analysis, the main results of demographic
variables, comorbidities, symptoms and self-reported severity
and extension of psoriasis in this subpopulation (European
patients with psoriasis without a diagnosis of psoriatic arthritis)
are summarized in Table 1 and below.
The number of adults in the households was larger in Spain
vs. other EC taken as a whole [2.53 (SD 1.11) vs. 2.30 (SD 1.09),
P < 0.001], as was the percentage of patients with psoriasis alone
(89% vs. 83%, P = 0.009).
Mean age was similar in patients from Spain and other EC
taken as a whole (52.0 years), and the same applies to the pro-
portion of men (47% of patients from Spain vs. 44% of patients
from other EC).
Regarding comorbidities, the mean body mass index was
higher in patients from Spain vs. the other EC (26.9 vs. 25.6,
P < 0.001). Patients from Spain vs. other EC reported a lower
prevalence of depression (6% vs. 12%, P = 0.002) and hyperten-
sion (15% vs. 21%, P = 0.007), but the prevalence of diabetes
was similar (10% vs. 9%, P = 0.775), as was heart disease (6%
vs. 6%, P = 0.773).
The difference in age of onset of psoriasis was not statistically
significant in patients from Spain vs. other EC [30.5 (SD 26.0)
vs. 29.7 (SD 18.1), P = 0.765]. There were some differences in
the location of psoriatic lesions by countries (Table 2). Patients
from Spain vs. other EC reported a significantly lower percent-
age of palmar and/or plantar (16% vs. 21%, P = 0.026), nail
(7% vs. 11%, P = 0.012) and scalp (33% vs. 42%, P = 0.001)
involvement, but more frequent involvement of elbows (49% vs.
42%, P = 0.020), ears (7% vs. 4%, P = 0.012), fingers/fingertips
(3% vs. 1%, P = 0.031), knuckles/dorsal hand (3% vs. 0.5%,
Table 1 Demographic data and main comorbidities, by country
Variable France
n = 349
Germany
n = 311
Italy
n = 359
Spain
n = 354
UK
n = 327
P value
Age, mean, median
[IQR], years
45.4, 43.0 [32.0; 57.0] 49.9, 51.0 [40.0; 61.0] 55.9, 57.0 [45.0; 69.0] 50.9, 50.0 [39.0; 61.0] 53.2, 54.0 [42.0; 66.0] <0.001
Age at onset, mean,
median [IQR], years
32.3, 25.0 [16.0; 40.0] 26.9, 20.0 [14.0; 35.0] 39.4, 35.0 [20.0; 52.0] 30.5, 26.0 [17.0; 42.5] 28.2, 24.0 [15.0; 39.0] <0.001
Gender, n (%)
Female 187 (53.6) 181 (58.2) 182 (50.7) 187 (52.8) 200 (61.2) 0.041
Male 162 (46.4) 130 (41.8) 177 (49.3) 167 (47.2) 127 (38.8)
BMI, median [IQR] 26.2 [23.3; 30.2] 25.4 [22.7; 28.8] 25.2 [23.1; 27.5] 26.8 [23.7; 29.7] 26.6 [24.0; 29.8] <0.001
BMI, n (%)
<25 117 (39.3) 144 (48.2) 174 (49.3) 119 (35.3) 102 (36.0) <0.001
25–30 96 (32.2) 92 (30.8) 140 (39.7) 140 (41.5) 113 (39.9)
30–35 62 (20.8) 49 (16.4) 31 (8.8) 58 (17.2) 44 (15.5)
>35 23 (7.7) 14 (4.7) 8 (2.3) 20 (5.9) 24 (8.5)
Depression, % 14.9 12.9 3.6 6.2 17.7 <0.001
Diabetes, % 6.9 10.9 8.6 9.9 10.7 0.345
Hypertension, % 12.9 29.6 19.2 14.7 24.8 <0.001
Heart disease, % 4.0 8.4 6.7 5.7 6.1 0.218
BMI, body mass index; IQR, interquartile range.
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P = 0.002), buttocks (5% vs. 2%, P = 0.002), legs (12% vs. 7%,
P = 0.005) and generalized lesions (2% vs. 1%, P = 0.022).
Itch was the most frequently reported bothersome skin symp-
tom, with percentages ranging from 31% (UK) to 41% (Spain),
but the differences were not significant. Other symptoms
reported as most bothersome by patients from Spain vs. other
EC were bleeding (4% vs. 2%, not significant), flaking (16% vs.
8%, P < 0.001) and stress/emotional impact (5% vs. 3%, not
significant).
The self-reported severity score of psoriasis at its worst, on a
scale from 1 to 10, varied by country (Table 2). The mean self-
reported severity was higher in patients from Spain vs. other EC
overall [5.92 (SD 2.71) vs. 5.33 (SD 2.57), P < 0.001]. Self-
reported severity generally correlated with the affected BSA,
based on self-reported palm counts at the time of the telephone
interview, but patients from Spain classified themselves in higher
categories of severity regardless of self-reported BSA (Fig. 1).
Patients from Spain vs. other EC were more likely to report
involvement of one to three palms (49% vs. 39%, P < 0.001),
whereas the proportions of patients reporting involvement of
>10 palms or >20 palms were lower (5% vs. 7% and 1% vs. 4%,
respectively, P < 0.001).
Overall, DLQI was inversely correlated with age (with a 0.5-
unit decrease for every 10 years) and directly correlated with
self-perceived severity (0.57 units of DLQI for each unit of self-
perceived severity). Nail involvement, scalp involvement or palm
and/or sole involvement were associated with significantly
greater impact on HRQoL, as measured by DLQI score
Table 2 Distribution of lesions, self-reported severity at its worst, most troublesome symptoms and extension of lesions (palms) at the
time of the telephone interview, by country
France
n = 349
Germany
n = 311
Italy
n = 359
Spain
n = 354
UK
n = 327
P value
Location, %
Face 21.5 15.8 7.0 5.9 13.5 <0.001
Hands (dorsa) 0.6 0.3 0.6 2.8 2.5 0.006
Palms 18.6 12.9 17.5 11.0 9.2 0.001
Nails 9.7 11.9 7.8 6.5 15.9 <0.001
Scalp 45.6 52.1 22.3 32.8 52.0 <0.001
Genital areas 6.3 10.6 4.5 5.4 7.0 0.019
Trunk 16.6 21.2 9.2 15.5 33.0 <0.001
Elbows 36.7 49.8 32.9 48.9 49.5 <0.001
Arms 1.4 1.3 4.7 5.9 8.0 <0.001
Knees 22.1 32.8 20.3 28.5 33.3 <0.001
Legs 3.7 6.1 7.2 12.1 12.5 <0.001
Soles 12.9 13.8 12.8 9.6 9.2 0.213
Generalized 0.0 1.9 0.3 2.0 0.3 0.003
Severity score of psoriasis at its worst, mean (SD) 4.8 (2.2) 5.8 (2.5) 4.9 (2.6) 5.9 (2.7) 5.9 (2.7) <0.001
Severity score categories, n (%) <0.001
Mild (1–3) 107 (31.7) 68 (21.7) 117 (33.7) 71 (19.9) 77 (23.4)
Moderate (4–7) 192 (56.8) 148 (47.1) 161 (46.4) 176 (49.4) 141 (42.9)
Severe (8–10) 39 (11.5) 98 (31.2) 69 (19.9) 109 (30.6) 111 (33.7)
Most bothersome symptom or feature, % <0.001
Itch 43.6 37.3 48.2 37.9 35.8
Scaling 11.2 26.7 16.2 10.2 7.7
Location or size of lesions 20.1 6.4 2.5 11.6 24.2
Area involved, n (%) <0.001
No skin lesions (<1 palm) 91 (26.1) 111 (35.7) 165 (46.0) 110 (31.1) 105 (32.1)
1–3 palms 165 (47.3) 118 (37.9) 93 (25.9) 174 (49.2) 145 (44.3)
4–10 palms 62 (17.8) 43 (13.8) 36 (10.0) 50 (14.1) 52 (15.9)
11–20 palms 10 (2.9) 9 (2.9) 16 (4.5) 12 (3.4) 15 (4.6)
>20 palms 8 (2.3) 11 (3.5) 24 (6.7) 5 (1.4) 7 (2.1)
Severity score categories in patients with BSA ≤3% palms, n (%) <0.001
Mild (1–3) 100 (40.8) 63 (27.8) 102 (40.8) 69 (24.5) 74 (29.7)
Moderate (4–7) 128 (52.2) 109 (48.0) 109 (43.6) 140 (49.7) 109 (43.8)
Severe (8–10) 17 (6.9) 55 (24.2) 39 (15.6) 73 (25.9) 66 (26.5)
BSA, body surface area.
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(differences ranging from 1.1 to 2.3, P < 0.01). Treatment, daily
activities and leisure were dimensions of DLQI largely affected
by nail involvement, whereas daily activities, symptoms and feel-
ings, and work and school were mainly determined by palm
and/or sole involvement, and work and school were affected by
scalp involvement.
The mean DLQI value in patients from Spain [4.70 (SD
4.26)] was lower than in patients from other EC [6.06 (SD 5.84),
P = 0.001], mostly because of a lower proportion of those with a
very large (6% vs. 12%) or extremely large (1% vs. 2%) effect on
patient’s life (Fig. 2). The mean scores for patients from Spain
were also lower than for patients from other EC in all the dimen-
sions of the questionnaire (symptoms and feelings, daily activi-
ties and personal relationships, P < 0.001; leisure and treatment,
P = 0.002; and work and school, P = 0.005). The proportions of
patients from Spain vs. other EC who scored 0 on DLQI
questions were also higher in all the dimensions of the MAPP
survey, respectively: symptoms and feelings (36% vs. 25%,
P = 0.001, and 63% vs. 39%, P < 0.001), daily activities (75%
vs. 59%, P < 0.001, and 62% vs. 48%, P < 0.001), leisure (72%
vs. 60%, P = 0.006, and 70% vs. 58%, P = 0.004), work and
school (69% vs. 56%, P = 0.001), personal relationships (87%
vs. 67%, P < 0.001, and 84% vs. 65%, P < 0.001) and treatment
(69% vs. 55%, P = 0.001).
There was a significant effect and interaction of country and
gender on DLQI values (P = 0.047). Only in Italy were DLQI
values significantly different according to the patients’ gender
(higher in women, P = 0.018), but women from Spain had sig-
nificantly lower DLQI values than those from France (P = 0.001)
and Germany (P = 0.026), and men from France had higher
DLQI values than those from any other country (P < 0.001).
Similar results were found for other DLQI dimensions with sig-
nificant interactions [daily activities (P = 0.033) and leisure
(P = 0.038)]; however, in the case of treatment, only women
from Spain had significantly lower values than UK women
(P = 0.016), and Italian men had significantly lower values than
their French (P < 0.001) and UK (P < 0.001) counterparts.
When the individual components of DLQI in patients
reporting some degree of impact on their emotional and
social well-being were stratified according to BSA and coun-
try, a better correlation with BSA categories was observed in
patients from Spain. Nevertheless, the impact on HRQoL was
lower for all dimensions except work and study; 50% of
patients from Spain with extensive disease (BSA > 10%) had
some degree of interference with their study or work vs. 16%
from other EC.
The probability of having seen an HCP was dependent on
BSA involvement; 61% of patients from other EC with involve-
ment of less than one palm had not seen an HCP in the past
12 months compared with 42% with one to three palms, 35%
with four to 10 palms and 41% with >10 palms. The correspond-
ing percentages in patients from Spain were 68%, 47%, 44% and
29%. In approximately 50% of patients from Spain with BSA
involvement >3% low expectations were the main reason for not
having seen an HCP, but differences in healthcare system or per-
sonal attitudes might explain the lower rate of non-frequenta-
tion of patients from Spain with the most extensive disease in
comparison with their EC counterparts.
Survey patients from Spain also differed from their EC coun-
terparts in frequentation of HCPs (mostly dermatologists): 17%
of patients from Spain had seen more than four HCPs in the last
year vs. 10% of patients from other EC (P < 0.001). For patients
from Spain vs. other EC, the top goal of treatment was keeping
symptoms at bay (33% vs. 38%, P < 0.001) and reducing flaking
(24% vs. 13%, P < 0.001), and Spanish patients were more likely
to achieve their main therapeutic goal (73% vs. 61%, P < 0.001).
Psoriatic arthritis may be underdiagnosed among patients in
Spain with a diagnosis of ‘psoriasis only’, as 34% of patients
33%
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reported joint pain or soreness, and sausage digits or heel pain
and/or swelling were reported to have occurred upon specific
questioning by 29% and 24% of patients, respectively.
The vast majority (84%) of survey patients from Spain with
psoriasis only were receiving no treatment whatsoever or just
topical treatment, regardless of the self-reported extension of
disease (Fig. 3), but 31% had discussed the possibility of sys-
temic treatment with their HCP, 13% had discussed biologic
treatment and 4% were actually receiving biologic treatment
(compared with 3% of EC patients).
Discussion
Multinational Assessment of Psoriasis and Psoriatic Arthritis,
the largest multinational probability survey of patients with pso-
riasis and/or psoriatic arthritis, was not biased by a specific clinic
or geographic region, and patients did not have to be under
medical care or enrolled in a patient association to participate.1
Questions for the MAPP survey were designed to determine why
patients find their psoriatic condition and/or treatment burden-
some and were based on validated HRQoL assessments, such as
the DLQI, as well as and qualitative factors related to medical
care.1 Results of the global MAPP patient survey revealed that
there is a high rate of undertreatment of psoriasis and a discon-
nect between patient-perceived disease severity and medical
assessment of disease severity.1 This report focuses on the find-
ings from the survey of European patients with psoriasis only,
and specifically in patients from Spain. The results demonstrate
the need for a local approach in defining therapeutic goals based
on patient-reported outcomes.
Some demographic differences may have arisen from sam-
pling; even though female employment rates are high in Europe,
a fixed-line residential telephone survey is more likely to be
answered by women. On the other hand, only one family mem-
ber could be included in the survey, even in households with
multiple cases of psoriasis.
The sample population from Spain was characterized by a
relatively high body mass index and a lower prevalence of
diagnosed depression compared with the other EC. The preva-
lence of cardiovascular comorbidities seems to be relatively
low for a psoriasis population, but the severity distribution is
likely to be more representative of the general population than
general practitioners and insurance claims databases. Differ-
ences in distribution may partially account for differences in
DLQI, as palmoplantar, nail and scalp psoriasis, which
occurred less frequently in the population from Spain, are
associated with higher DLQI values. The self-perceived severity
of psoriasis at its worst was slightly but significantly higher in
patients from Spain than from other EC, and there were also
significant differences in the symptoms perceived as most
bothersome, even though itch was predominant (41%), irre-
spective of country.
Self-reported severity of psoriasis at its worst generally
correlated with self-reported BSA involvement at the time of the
survey, but the trend reversed in patients from Spain, who
scored high in self-reported severity and had relatively low BSA
estimations; 26% of these patients with a BSA ≤3% palms rated
their disease as severe.
Several variables have been found to affect DLQI and their
dimensions, including BSA, age, gender and specific locations
characterized by visibility, pruritus or dexterity impairment, but
country-specific variability is the most remarkable finding, and
the results of the present study are consistent with the acknowl-
edged limitations of DLQI as regards cross-cultural equiva-
lence.3,6 Although the DLQI is designed to help determine the
level of HRQoL impairment, the majority of the questions are
influenced by external factors, including age, gender, diagnosis
and nationality.7
Our results show some similarities to those of prior observa-
tional studies of Spanish patients with psoriasis.8–10 In an
observational study evaluating HRQoL in 395 patients with
psoriasis, factors associated with impaired HRQoL included age
(with greater impact in younger patients), female gender and
greater BSA involvement.8 In addition, among the DLQI
domains, cutaneous symptoms (i.e. itching and pain) had the
greatest effect on HRQoL. ARIZONA, a large, cross-sectional,
observational study conducted in Spain, evaluated comorbidi-
ties in 1022 patients with moderate-to-severe psoriasis.9 The
most common comorbidities associated with psoriasis were
dyslipidemia (28.1% of patients), obesity (26.0%), psoriatic
arthritis (21.8%) and hypertension (18.3%). Another analysis
of the ARIZONA study data found that the mean DLQI score
significantly varied among age groups, with greater adverse
effects on HRQoL observed in younger patients vs. older
patients.10
Overall, patients from Spain had lower mean and median
DLQI scores, global and in all dimensions, than their counter-
parts from other EC. These patients, regardless of BSA
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Figure 3 Treatment categories by self-reported involvement in
Spanish patients.
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involvement, were less likely to report an impact on DLQI vs.
patients from other EC for all dimensions except work and
study; 50% vs. 16% with BSA involvement >10% had some
degree of interference with their study or work, as measured by
DLQI.
In a previous study, patients from some EC, including Italians
and Belgians, experienced significantly less ‘problems with loved
ones’ (item 8 of DLQI) and ‘sexual difficulties’ (item 9) because
of their psoriasis compared with patients from other countries
who had similar levels of disability measured by the DLQI.6
These patients may be less self-conscious during physical inti-
macy because of psychological differences, such as identification,
coping and negation, between different cultures.6 Likewise,
observed differences across countries may be due to different
interpretation of scores and/or response patterns.6 In the present
study, the lowest mean DLQI values corresponded to Spain and
Italy, and the highest to France. This was mainly due to differ-
ences in the percentages of patients scoring in the extreme bands
of DLQI, and especially those reporting ‘no effect’ of psoriasis
on their HRQoL.
Finally, the present study suggests that patients from Spain
may differ from those in other EC included in this survey with
regard to the frequency of HCP visits, their described therapeu-
tic goals and the degree to which these goals were achieved.
Based on their reported signs and symptoms, some patients in
the Spanish and the other EC cohorts may have undiagnosed
psoriatic arthritis. In addition, very small percentages of both
cohorts reported receiving biologic treatments (3–4%) for their
psoriasis.
In conclusion, the Spanish cohort in the MAPP survey,
although sharing many similarities with the other EC cohort,
have a number of intriguing differences which may require fur-
ther exploration.
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